NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee D meeting minutes

**Minutes:** Confirmed

**Date:** Wednesday 14 June 2023

**Location:** Via Zoom

## Attendees

Committee members present

1. Dr Megan John (Chair) Present for all items
2. Dr Stephen Smith (Vice-chair) Present for all items
3. Dr Matthew Bradley Items 1 to 4.2.2
4. Elliott Dash Present for all items
5. Professor Sofia Dias Present for all items
6. Professor Rachel Elliott Present for all items
7. Dr Andrew Hitchings Present for all items
8. Dr Robert Hodgson Present for all items
9. Dr Bernard Khoo Items 1 to 5.2
10. Dr Ivan Koychev Items 1 to 5.2
11. Dr Philip Mallender Present for all items
12. Giles Monnickendam Present for all items
13. Dr Nathan Moore Present for all items
14. Dr Malcolm Oswald Present for all items
15. Dr Rebecca Payne Present for all items
16. Carole Pitkeathley Present for all items
17. Dr Raju Reddy Present for all items
18. Dr Ben Searle Present for all items
19. Professor John Watkins Present for all items

NICE staff (key players) present

Linda Landells, Associate Director Present for all items

Celia Mayers, Project Manager Items 1 to 4.2.2

Caron Jones, Heath Technology Assessment Adviser Items 1 to 4.2.2

Nigel Gumbleton, Heath Technology Assessment Analyst Items 1 to 4.2.2

Anita Sangha, Heath Technology Assessment Analyst Items 5 to 5.2.2

External assessment group representatives present

Janette Greenhalgh, Liverpool Reviews and Implementation Group (LRIG), Items 1 to 4.1.3

James Mahon, Liverpool Reviews and Implementation Group (LRIG), Items 1 to 4.1.3

Hesam Ghiasvand, Warwick Evidence Items 5 to 5.1.3

Bethany Shinkins, Warwick Evidence Items 5 to 5.1.3

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drug Fund Clinical Lead, NHS England, Items 5 to 5.2.2

Rakesh Popat, Consultant Haematologist, Clinical Expert, nominated by GlaxoSmithKline, Items 5 to 5.1.3

Shelagh McKinlay, Patient expert, nominated by Myeloma UK, Items 5 to 5.1.3

*Please note that alongside the attendees listed in this document, there were additional NICE Staff present in this meeting. These attendees were not involved in the decision making or discussions.*

## Minutes

### Introduction to the meeting

* 1. The chair Dr Megan John welcomed members of the committee and other attendees present to the meeting.
	2. The chair noted apologies from Andrew Fox, Professor Chris Parker, Christopher Herring, Professor David Meads, Dr Guy Makin and Martin Bradley.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meetings held on Thursday 13 April and Thursday 11 May 2023.

### Appraisal of voxelotor for treating haemolytic anaemia caused by sickle cell disease [ID1403]

* 1. Part 1 – Open session
		1. The chair welcomed the external assessment group representatives, members of the public and company representatives from Pfizer.
		2. The chair asked all committee members, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10505/documents).
		3. The Chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached by consensus.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10505>

### Appraisal of belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

* 1. Part 1 – Open session
		1. The chair Dr Stephen Smith welcomed the invited experts, external assessment group representatives, members of the public and company representatives from GlaxoSmithKline.
		2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered. Declarations for this appraisal can be found on the Topic Register of Interest (TROI) on the topic webpage, [here](https://www.nice.org.uk/guidance/indevelopment/gid-ta10568/documents).
		3. The Chair led a discussion of the consultation comments presented to the committee.
	2. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
		1. The committee then agreed on the content of the Draft Guidance (DG) or Final Draft Guidance (FDG). The committee decision was reached through a vote by members.
		2. The committee asked the NICE technical team to prepare the Draft Guidance (DG) or Final Draft Guidance (FDG) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10568>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee D will be held on Wednesday 12 July 2023 and will start promptly at 09:15